Avocates et Avocats Iliana Djagova
Iliana Djagova

Iliana Djagova

Associée
lic. iur., LL.M., Avocate

Icon Vcard vCard LinkedIn

Site

Zurich

Contact

Téléphone direct: +41 58 658 56 98
iliana.djagova@walderwyss.com

Curriculum vitae

Télécharger le PDF

Domaines d'activité: Corporate / M&A Contrats commerciaux Marchés des capitaux

Iliana Djagova is a partner in the Corporate/M&A team of Walder Wyss. She has extensive experience advising on complex domestic and cross-border M&A transactions, growth equity financings and late-stage investments. She regularly acts for strategic and financial investors, including private equity firms, on both the buy-side and sell-side. Iliana Djagova also advises companies and shareholders throughout all stages of their lifecycle, with a particular focus on growth-stage and exit transactions. In addition, she counsels private and listed companies, as well as their shareholders, on corporate governance and general corporate and commercial law matters.

Prior to joining Walder Wyss in 2023, Iliana Djagova spent eight years at another leading Swiss law firm, advising on high-profile M&A and private equity transactions. In 2015/16 she further broadened her international experience at Willkie Farr & Gallagher LLP in New York, USA.

Iliana Djagova studied law at the University of Geneva and Zurich (lic. iur., 2010) and the University of California, Berkeley (LL.M., 2015). She was admitted to the Zurich Bar in 2013 and to the New York Bar in 2018.

Iliana Djagova’s professional languages are German and English. She also speaks Bulgarian and French.

Biotech Company CRISPR Therapeutics (NASDAQ) issued USD 600M Convertible Notes

SIS Medical AG – Investment by Claret Capital Partners

Promotions chez Walder Wyss

Tender offer for u-blox successfully completed

Swiss MedTech company Distalmotion SA closes USD 150m Series G Financing Round

IFLR 1000 Rankings 2025 - Walder Wyss as a top-performing law firm ranked

Corient acquires Stonehage Fleming and Stanhope Capital

Public Tender Offer for SIX-listed u-blox

SoftwareOne successfully completes its tender offer for Crayon

Walder Wyss advised Novo Holdings on the acquisition of Catalent

SoftwareOne to launch tender offer for all outstanding Crayon shares

Alentis Therapeutics Raises USD 181.4m in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors

Boehringer Ingelheim acquires veterinary therapeutic vaccines developer Saiba Animal Health

Swixx Biopharma acquires Biopas to enter Latin America

SOPHiA GENETICS SA closed secured term loan financing

Walder Wyss advised CRISPR Therapeutics (NASDAQ) on USD 280 Million Equity Issuance

Walder Wyss advised Nasdaq listed Altamira Therapeutics in its sale of majority stake in Altamira Medica

Switzerland: A Corporate/M&A Overview

| par Hans-Jakob Diem, Alex Nikitine et Iliana Djagova | dans: Chambers Global 2026

Commentary on art. 659-659b and 783 CO re Treasury Shares (Online Update)

| par Iliana Djagova et Sarah Vettiger | Basler Kommentar zum Obligationenrecht II | edit.: in: Rolf Watter/Hans-Ueli Vogt (Editor[s]) | «Commentary on art. 659-659b and 783 CO re Treasury Shares (Online Update)»

Reconnaissances


Chambers Practice Guide - Equity Finance 2024
Chambers Global 2026
IFLR1000 Rising Start Lawyer

Autres avocats